CN100358893C - 一些新的咪唑并吡啶及其用途 - Google Patents

一些新的咪唑并吡啶及其用途 Download PDF

Info

Publication number
CN100358893C
CN100358893C CNB03823193XA CN03823193A CN100358893C CN 100358893 C CN100358893 C CN 100358893C CN B03823193X A CNB03823193X A CN B03823193XA CN 03823193 A CN03823193 A CN 03823193A CN 100358893 C CN100358893 C CN 100358893C
Authority
CN
China
Prior art keywords
pyridine
imidazo
bromo
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB03823193XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1684964A (zh
Inventor
亨里克·约翰森
卡罗利纳·拉维茨
格里戈里奥斯·尼基蒂迪斯
彼得·斯乔
彼得·斯托姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1684964A publication Critical patent/CN1684964A/zh
Application granted granted Critical
Publication of CN100358893C publication Critical patent/CN100358893C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB03823193XA 2002-08-14 2003-08-13 一些新的咪唑并吡啶及其用途 Expired - Fee Related CN100358893C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE02024628 2002-08-14
SE0202462A SE0202462D0 (sv) 2002-08-14 2002-08-14 Novel use

Publications (2)

Publication Number Publication Date
CN1684964A CN1684964A (zh) 2005-10-19
CN100358893C true CN100358893C (zh) 2008-01-02

Family

ID=20288750

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB03823193XA Expired - Fee Related CN100358893C (zh) 2002-08-14 2003-08-13 一些新的咪唑并吡啶及其用途

Country Status (18)

Country Link
US (1) US7410966B2 (https=)
EP (1) EP1539759B1 (https=)
JP (1) JP2006503010A (https=)
KR (1) KR20060005333A (https=)
CN (1) CN100358893C (https=)
AT (1) ATE370138T1 (https=)
AU (1) AU2003251272A1 (https=)
BR (1) BR0313461A (https=)
CA (1) CA2495511A1 (https=)
DE (1) DE60315674T2 (https=)
ES (1) ES2290538T3 (https=)
IL (1) IL166413A0 (https=)
MX (1) MXPA05001581A (https=)
NO (1) NO20051265L (https=)
NZ (1) NZ538156A (https=)
SE (1) SE0202462D0 (https=)
WO (1) WO2004016611A1 (https=)
ZA (1) ZA200500887B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011242B1 (ru) 2004-03-25 2009-02-27 Янссен Фармацевтика Н.В. Производные имидазола
RU2007101544A (ru) 2004-06-17 2008-08-10 Уайт (Us) Антагонисты рецепторов высвобождающего гонадотропин гормона
RU2007101509A (ru) 2004-06-17 2008-07-27 Уайт (Us) Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин
US7799778B1 (en) * 2005-01-12 2010-09-21 Alcon, Inc. 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
WO2007007919A2 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN101208339B (zh) 2005-08-01 2010-12-29 霍夫曼-拉罗奇有限公司 杂环苄基氨基衍生物，它们的制备以及作为药剂的应用
BRPI0503681A (pt) 2005-08-19 2007-04-10 Fundacao Oswaldo Cruz compostos azóis usados como agentes tuberculostáticos e leishmanicidas, composições farmacêuticas contendo os mesmos, uso das respectivas composições farmacêuticas no tratamento ou inibição de doenças, bem como método de tratamento ou inibição de doenças
UY29823A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
US8334290B2 (en) 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
EP1963315B1 (en) * 2005-12-22 2014-10-08 Cancer Research Technology Limited Enzyme inhibitors
US20090170847A1 (en) * 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
ITMI20061581A1 (it) * 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
NZ578944A (en) * 2007-02-13 2011-03-31 Ab Science PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS
RU2009135616A (ru) * 2007-03-30 2011-05-10 Астразенека Аб (Se) НОВЫЕ АМИДАЗО[4,5-b]ПИРИДИН-7-КАРБОКСАМИДЫ 704
WO2008121064A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
WO2009001021A1 (en) * 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
KR101703941B1 (ko) * 2008-11-10 2017-02-07 내셔날 헬스 리서치 인스티튜트 티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
AU2011308256B2 (en) * 2010-09-28 2015-08-20 Daewoong Pharmaceutical Co., Ltd. Novel method of preparing benzoimidazole derivatives
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103724331A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
EP3253754B1 (en) * 2015-02-02 2021-03-31 Kancera AB 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
AU2016317049A1 (en) 2015-08-31 2018-03-15 Pharmacyclics Llc BTK inhibitor combinations for treating multiple myeloma
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
CN109563092B (zh) * 2016-07-11 2021-09-14 坎塞拉有限公司 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
AU2017355544A1 (en) 2016-11-03 2019-05-16 Juno Therapeutics, Inc. Combination therapy of a T cell therapy and a BTK inhibitor
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
EP4107151A1 (en) 2020-02-18 2022-12-28 Bayer Aktiengesellschaft Heteroaryl-triazole compounds as pesticides
CN113582988B (zh) * 2020-04-30 2025-09-09 正大天晴药业集团股份有限公司 吡啶并环类化合物及其医药用途
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049407A1 (de) * 1980-10-03 1982-04-14 Dr. Karl Thomae GmbH 6-Hydroxy-2-phenyl-imidazo(4,5-b)pyridine, ihre Herstellung und diese enthaltende Arzneimittel
EP0494071A2 (en) * 1990-12-31 1992-07-08 Fujisawa Pharmaceutical Co., Ltd. Trifluoromethylketone tripeptide derivatives
WO2001096336A2 (en) * 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985891A (en) * 1973-02-03 1976-10-12 Boehringer Ingelheim Gmbh 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof
BR0116113A (pt) * 2000-12-12 2004-08-03 Neurogen Corp Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049407A1 (de) * 1980-10-03 1982-04-14 Dr. Karl Thomae GmbH 6-Hydroxy-2-phenyl-imidazo(4,5-b)pyridine, ihre Herstellung und diese enthaltende Arzneimittel
EP0494071A2 (en) * 1990-12-31 1992-07-08 Fujisawa Pharmaceutical Co., Ltd. Trifluoromethylketone tripeptide derivatives
WO2001096336A2 (en) * 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles

Also Published As

Publication number Publication date
BR0313461A (pt) 2005-07-05
EP1539759B1 (en) 2007-08-15
DE60315674T2 (de) 2008-06-19
MXPA05001581A (es) 2005-04-25
SE0202462D0 (sv) 2002-08-14
AU2003251272A1 (en) 2004-03-03
IL166413A0 (en) 2006-01-15
ES2290538T3 (es) 2008-02-16
WO2004016611A1 (en) 2004-02-26
KR20060005333A (ko) 2006-01-17
ATE370138T1 (de) 2007-09-15
JP2006503010A (ja) 2006-01-26
DE60315674D1 (de) 2007-09-27
NO20051265L (no) 2005-05-12
NZ538156A (en) 2006-09-29
US7410966B2 (en) 2008-08-12
EP1539759A1 (en) 2005-06-15
CN1684964A (zh) 2005-10-19
US20050261333A1 (en) 2005-11-24
CA2495511A1 (en) 2004-02-26
ZA200500887B (en) 2006-02-22

Similar Documents

Publication Publication Date Title
CN100358893C (zh) 一些新的咪唑并吡啶及其用途
JP6355648B2 (ja) Ｗｎｔシグナル伝達経路の３−（ベンゾイミダゾール−２−イル）−インダゾール阻害剤およびそれらの治療的使用
KR102924294B1 (ko) 아졸-융합된 피리다진-3(2h)-온 유도체
ES2320984T3 (es) Inhibidores de fab i.
CN115335043A (zh) Pgdh抑制剂以及制备和使用方法
JP2022024019A (ja) Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
EP2751108B1 (en) Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN105073751B (zh) 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑
JP5355582B2 (ja) ベンゾジアゼピン化合物及び医薬組成物
US20080234261A1 (en) Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors
CN114072409B (zh) 炔类衍生物及其制备方法和用途
CN107072985A (zh) 治疗性抑制化合物
TW201321371A (zh) 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
JP2007522142A (ja) Ｉｋｋ３に対して活性を有するベンゾイミダゾール置換チオフェン誘導体
JP2024525606A (ja) ピリジノンｍｋ２阻害剤及びその使用
CN114845996A (zh) 一种含苯环的化合物及其应用
WO2024040768A1 (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN114901642B (zh) 一种稠环化合物及其应用
WO2025077857A1 (zh) Prmt5抑制剂在治疗肿瘤或癌症中的用途
CN114671878B (zh) 取代的含氮双环化合物及其用途
ES2715348T3 (es) Compuestos que contienen anillos de nitrógeno fusionados para su uso como antagonistas de CRTH2
RU2797613C2 (ru) Производные 1,2,4-оксадиазола в качестве ингибиторов гистондезацетилазы 6
HK40107306A (zh) 吡啶酮mk2抑制剂及其用途
BR112020010534B1 (pt) Derivados de 1,2,4-oxadiazol, seus usos como inibidores de histona desacetilase 6 e composição farmacêutica compreendendo os mesmos
HK40070437A (en) Compound containing benzene ring and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080102

Termination date: 20090914